ATAI
Atai Beckley N.V·Healthcare
3.64
1.622%(−0.06)
Market ClosedLast Updated: — ET
52W L: $1.2852W H: $6.75
ATAI NEWS
proactiveinvestors.com
2d ago
Ceres Power shares fall 8.6% as broker downgrades to 'sell' on valuation concerns
Ceres Power Holdings PLC (LSE:CWR, OTC:CPWHF) fell 7% to 320p on Thursday after Peel Hunt downgraded the fuel cell technology developer to 'sell' from...
seekingalpha.com
3d ago
AtaiBeckley: 'Buy' On New Key Developments For BPL-003 For TRD
AtaiBeckley maintains a "Buy" rating, driven by key pipeline advances in psychedelic-based treatments for treatment-resistant depression. The company's BPL-003 achieved robust, rapid, and statistically significant reductions in MADRS scores in phase 2b, supporting upcoming parallel phase 3 ReConnection studies. The company secured FDA alignment for two pivotal phase 3 trials, with first patient dosing targeted for Q2 2026 and topline data expected in 2029.
benzinga.com
3d ago
AtaiBeckley Depression Drug Delivers Rapid Day-2 Antidepressant Response
The company reported a 66.7% antidepressant response rate at Day 2, which has contributed to the stock's upward momentum as broader markets experienced gains on Tuesday.
proactiveinvestors.com
3d ago
AtaiBeckley reports rapid response in Phase 2a trial of depression drug BPL-003
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) announced that patients in a mid-stage trial of its experimental depression treatment BPL-003 showed improvement within two days of a single dose, with effects lasting up to 12 weeks. The Phase 2a study found that 66.7% of participants achieved a clinically significant reduction in symptoms by Day 2.
globenewswire.com
3d ago
AtaiBeckley's BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs
NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced peer-reviewed Phase 2a results (NCT05660642) in CNS Drugs demonstrating that a single intranasal dose of BPL-003 (mebufotenin benzoate), which holds FDA Breakthrough Therapy Designation, achieved rapid and sustained reductions in MADRS scores from baseline in participants with treatment-resistant depression (TRD) who remained on stable SSRI therapy throughout the study (n=12). A 66.7% antidepressant response rate (≥50% reduction from baseline MADRS score) was observed at Day 2 in both the 10 mg (n=6) and 12 mg (n=6) cohorts, with 83% (5/6) of participants in the 10 mg cohort and 66.7% (4/6) of participants in the 12 mg cohort maintaining a response at Week 12. BPL-003 was generally well tolerated with no serious adverse events reported, and participants achieved a mean discharge approximately 100 minutes post-dose. Phase 3 studies are on track to initiate in Q2 2026 following recent FDA End-of-Phase 2 (EOP2) alignment.
proactiveinvestors.ca
Mar 27
AtaiBeckley awarded ‘Buy' rating in initial coverage from Deutsche Bank analysts
Deutsche Bank has initiated coverage on AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) assigning a 'Buy' rating and setting a price target of $12, implying potential upside of around 320% from current levels. In a note to clients, analysts highlighted the company's position in the emerging field of psychedelic medicine for mental health.
